Intech Investment Management LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 9.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 50,653 shares of the company’s stock after purchasing an additional 4,505 shares during the quarter. Intech Investment Management LLC’s holdings in AbbVie were worth $13,250,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently bought and sold shares of ABBV. Financial Freedom LLC purchased a new stake in shares of AbbVie in the 3rd quarter valued at $29,000. Burk Holdings LLC purchased a new position in shares of AbbVie during the second quarter worth $30,000. Marquette Asset Management LLC raised its holdings in shares of AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the last quarter. IMG Wealth Management Inc. raised its holdings in shares of AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares during the last quarter. Finally, Principia Wealth Advisory LLC lifted its position in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 44 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.
AbbVie Trading Down 0.3%
Shares of ABBV stock opened at $294.18 on Tuesday. The company has a market capitalization of $520.00 billion, a P/E ratio of 50.63, a P/E/G ratio of 1.34 and a beta of 0.20. The business’s 50 day moving average is $276.27 and its two-hundred day moving average is $241.28. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. AbbVie’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $1.86 earnings per share. On average, research analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.
AbbVie Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s payout ratio is 125.30%.
Wall Street Analyst Weigh In
ABBV has been the topic of several recent research reports. Leerink Partners upped their price target on shares of AbbVie from $309.00 to $342.00 and gave the company an “outperform” rating in a report on Monday, November 2nd. Barclays increased their price target on AbbVie from $325.00 to $335.00 and gave the stock an “overweight” rating in a research report on Monday. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. BMO Capital Markets set a $315.00 price objective on AbbVie in a report on Wednesday, November 4th. Finally, BNP Paribas Exane upped their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $297.85.
Check Out Our Latest Stock Analysis on AbbVie
Insider Transactions at AbbVie
In related news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This trade represents a 32.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Articles
- Five stocks we like better than AbbVie
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
